Ascend partners with Stanford School of Medicine to estimate exposure to SARS-CoV-2 in US dialysis population.
M2 EQUITYBITES-June 18, 2020-Ascend partners with Stanford School of Medicine to estimate exposure to SARS-CoV-2 in US dialysis population
(C)2020 M2 COMMUNICATIONS http://www.m2.com
Dialysis testing laboratory Ascend said on Wednesday that it is collaborating with the Stanford University School of Medicine to study the prevalence of SARS-CoV-2 antibodies in a nationwide sample of dialysis patients.
The study will begin in July 2020 and is expected to last up to one year. It focuses on 30,000 dialysis patients who need to interact with the healthcare system to receive life-sustaining therapy, even during the COVID-19 pandemic.
Patients in this vulnerable population cannot quarantine themselves, so it is crucial to understand their exposure status and highlight any differences between age groups and other regional factors. The study aims to estimate the exposure to the virus that causes COVID-19 in the US dialysis population and understand the rates of protective immunity over time.
In a short-term follow-up, the study will also help estimate the potential need for healthcare capacity and vaccine requirements to support this high-risk patient population in future waves of COVID-19.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jun 18, 2020|
|Previous Article:||Beep chosen for Automated Vehicle Transparency and Engagement for Safe Testing Initiative.|
|Next Article:||G4S' trading update for first five months of 2020 impacted by COVID-19 pandemic.|